M30/M65 ratio predicts the outcome of paclitaxel chemotherapy for NSCLC.

about

M30/M65 ratio predicts the outcome of paclitaxel chemotherapy for NSCLC.

Item

http://www.wikidata.org/entity/Q51226881

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

M30/M65 ratio predicts the outcome of paclitaxel chemotherapy for NSCLC.

@en

M30/M65 ratio predicts the outcome of paclitaxel chemotherapy for NSCLC.

@nl

type

Item

label

M30/M65 ratio predicts the outcome of paclitaxel chemotherapy for NSCLC.

@en

M30/M65 ratio predicts the outcome of paclitaxel chemotherapy for NSCLC.

@nl

prefLabel

M30/M65 ratio predicts the outcome of paclitaxel chemotherapy for NSCLC.

@en

M30/M65 ratio predicts the outcome of paclitaxel chemotherapy for NSCLC.

@nl

P1476

M30/M65 ratio predicts the outcome of paclitaxel chemotherapy for NSCLC.

@en

P2093

B Han

http://www.w3.org/2001/XMLSchema#string

L Jiang

http://www.w3.org/2001/XMLSchema#string

T Chu

http://www.w3.org/2001/XMLSchema#string

W Ying

http://www.w3.org/2001/XMLSchema#string

P2860

Ultrasound triggered image-guided drug delivery to inhibit vascular reconstruction via paclitaxel-loaded microbubbles.

Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer.

How Taxol/paclitaxel kills cancer cells.

Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18.

Small cell lung cancer: the importance of the extracellular matrix.

Anti-proliferative activity and cell cycle arrest induced by evodiamine on paclitaxel-sensitive and -resistant human ovarian cancer cells

Detection of epithelial cell death in the body by cytokeratin 18 measurement.

Combination Therapy using Co-encapsulated Resveratrol and Paclitaxel in Liposomes for Drug Resistance Reversal in Breast Cancer Cells in vivo

Mechanisms involved in lung cancer development in COPD.

MMP9 activation triggered by epidermal growth factor induced FoxO1 nuclear exclusion in non-small cell lung cancer.

P2888

s12094-016-1533-x

P304

326-331

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12094-016-1533-X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-07-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27468866

http://www.w3.org/2001/XMLSchema#string